TearLab (OTCMKTS: TEAR) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare TearLab to similar companies based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, earnings, dividends and risk.
This is a breakdown of current ratings and price targets for TearLab and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares TearLab and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TearLab||$27.12 million||-$16.10 million||-0.10|
|TearLab Competitors||$1.54 billion||$111.98 million||-141.70|
TearLab’s rivals have higher revenue and earnings than TearLab. TearLab is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares TearLab and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
TearLab has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, TearLab’s rivals have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.
Insider & Institutional Ownership
15.5% of TearLab shares are held by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 12.0% of TearLab shares are held by insiders. Comparatively, 16.3% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
TearLab beats its rivals on 7 of the 13 factors compared.
TearLab Company Profile
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
Receive News & Ratings for TearLab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab and related companies with MarketBeat.com's FREE daily email newsletter.